Yukio Kageyama
Overview
Explore the profile of Yukio Kageyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
105
Citations
1049
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fuchizawa H, Ando K, Motoi N, Iizuka T, Inoue M, Mitani K, et al.
Anticancer Res
. 2024 Apr;
44(5):1925-1930.
PMID: 38677727
Background/aim: Pembrolizumab, a second-line therapy for platinum-refractory advanced urothelial carcinoma (UC), is needed to improve objective response rate. Hence, it is crucial to identify optimal predictive biomarkers of responses. This...
2.
Ikeda R, Matsuoka Y, Inoue M, Ishikawa A, Akagi K, Kageyama Y
IJU Case Rep
. 2024 Mar;
7(2):115-119.
PMID: 38440716
Introduction: The efficacy of olaparib for treatment-related neuroendocrine prostate cancer is unknown. Here, we report a case of treatment-related neuroendocrine prostate cancer with a mutation that was treated with olaparib...
3.
Sekiguchi Y, Nishimura Y, Kanda H, Kawamura M, Kobayashi K, Mitani K, et al.
Gan To Kagaku Ryoho
. 2023 Oct;
50(9):985-992.
PMID: 37800294
An 84-year-old female developed gross hematuria. She was diagnosed as urinary bladder carcinoma. She was initiated on concurrent atezolizumab plus radiation(a phase Ⅱ clinical trial)(jRCT2031180060). After 8 cycles of atezolizumab,...
4.
Ando K, Kurashina R, Motoi N, Iizuka T, Inoue M, Maruyama R, et al.
Biochem Biophys Res Commun
. 2023 Jul;
676:165-170.
PMID: 37517219
Immune checkpoint inhibitor (ICI) therapy has been established for patients with advanced urothelial cancer (UC). The necessity of overcoming resistance to ICIs and identifying a predictive factor for the same...
5.
Kimura T, Ishikawa H, Nagumo Y, Sekino Y, Kageyama Y, Ushijima H, et al.
Int J Radiat Oncol Biol Phys
. 2023 May;
117(3):644-651.
PMID: 37196834
Purpose: To evaluate the safety and pathologic complete response (pCR) rate of radiation therapy with atezolizumab as bladder-preserving therapy for invasive bladder cancer. Methods And Materials: A multicenter, phase 2...
6.
Yoshida S, Takahara T, Arita Y, Ito M, Hayakawa S, Oguchi T, et al.
BMC Urol
. 2023 Mar;
23(1):33.
PMID: 36879257
Background: The significance of metastasis-directed therapy for oligometastatic prostate cancer has been widely discussed, and targeted therapy for progressive sites is a feasible option as a multidisciplinary treatment for castration-resistant...
7.
Kurashina R, Ando K, Inoue M, Maruyama R, Mitani K, Takenobu H, et al.
Cancer Diagn Progn
. 2023 Mar;
3(2):230-235.
PMID: 36875313
Background/aim: Several prognostic risk factors have been recognized when using cisplatin-based conventional chemotherapy for the treatment of advanced urothelial carcinoma (UC); these include performance status (PS), liver metastasis, hemoglobin (Hb)...
8.
Soma T, Fukuda S, Matsuyama Y, Ikeda R, Inoue M, Waseda Y, et al.
Int J Urol
. 2023 Mar;
30(6):532-538.
PMID: 36855807
Objectives: Postoperative inguinal hernia (IH) is one of the most common complications of radical prostatectomy (RP) including robot-assisted RP (RARP). However, a procedure to prevent IH after RARP has not...
9.
Izumi K, Inoue M, Washino S, Shirotake S, Kagawa M, Takeshita H, et al.
Int J Urol
. 2022 Dec;
30(9):714-721.
PMID: 36541136
Objectives: Although nivolumab plus ipilimumab has become a standard treatment regimen for metastatic clear cell renal cell carcinoma (ccRCC), its efficacy in non-clear cell carcinoma (nccRCC) has not been fully...
10.
Ikeda R, Matsuoka Y, Fukui N, Inoue M, Ishikawa A, Kageyama Y
Urol Case Rep
. 2022 Sep;
45:102227.
PMID: 36164376
Large cell calcifying Sertoli tumor is an uncommon testicular neoplasm. We present a case of a 36-year-old man with a late-onset large cell calcifying Sertoli tumor that resulted in a...